Abstract: Artemether-lumefantrine (AL) is a first-line treatment for uncomplicated malaria. Absorption of lumefantrine (LUM) is fat dependent, and in children, intake is recommended with milk. We investigated whether oil-fortified maize porridge can be an alternative when milk is not available. In an open-label pharmacokinetic study, Ugandan children <5 years with uncomplicated Plasmodium falciparum malaria were randomized to receive standard six-dose AL treatment [one tablet (20 mgA/120 mg LUM) if <15 kg and two tablets if >15 kg] with milk (A) or maize porridge plus oil (B). Parametric two-sample t-test was used to compare relative oral LUM bioavailability. The primary end-point was LUM exposure till 8 hr after the first dose (AUC 0-8 hr ). Secondary outcome included day 7 concentrations (d7 LUM ), LUM exposure between days 7 and 28 (AUC d7-28 ) and day 28 PCR-adjusted parasitological response. Evaluable children (n = 33) included 16 in arm A and 17 in arm B. The AUC 0-8 hr was comparable between A and B [geometric mean (95% CI): 6.01 (3.26-11.1) versus 6.26 (4.5-8.43) hr*lg/mL, p = 0.9]. Less interindividual variability in AUC 0-8 hr was observed in B (p = 0.01), but d7 LUM and AUC d7-28 were comparable. Children receiving two tablets had significantly higher exposure than those receiving one tablet [median d7 LUM (505 versus 289 ng/mL, p = 0.02) and AUC d7-28 (108 versus 41 hr*lg/mL, p = 0.006)]. One parasitological failure (d28 recrudescence) was observed. Our findings suggest that oil-fortified maize porridge can be an alternative to milk in augmenting absorption of LUM. The lower LUM exposure observed in children dosed with one AL tablet needs further attention.
The majority of deaths from falciparum malaria occur in children below the age of 5 years living in poor-resourced sub-Saharan Africa [1] . Artemether-lumefantrine (AL), the first co-formulated oral artemisinin combination, has been selected by several countries, including Uganda, as first-line treatment for uncomplicated Plasmodium falciparum malaria [2, 3] .
Artemether is a potent rapidly acting antimalarial, but has a very short half-life, t 1/2 (≤1 hr) [4] . Lumefantrine (LUM), less potent but long-acting schizontocide [(t 1/2 ) of 3-10 days], eliminates residual parasites left after massive clearance by artemether and its metabolite [4, 5] . Risk of late treatment failure is attributable to suboptimal LUM exposure [4] [5] [6] [7] . Oral bioavailability of LUM is highly variable and the importance of dietary fat to augment LUM absorption is well-established [8] [9] [10] . Milk or fatty food supplement is recommended to augment AL absorption [11] . Although AL is increasingly available for the treatment of malaria in endemic areas [12] [13] [14] [15] , milk or a fatty meal may not be available in resource-limited communities [10] . Thus, the need to identify appropriate food alternatives to ensure optimal effects of AL among user populations.
Among healthy volunteers, we observed comparable LUM exposure when AL was given with milk or oil-fortified maize porridge [16] . Drug absorption among children suffering from P. falciparum malaria may be different from that in healthy adults [4, 17] . The present study thus aimed at elucidating whether oil-fortified maize porridge can be recommended as alternative to milk for children treated with AL for uncomplicated malaria.
Methods
Study setting and study individuals. Inclusion criteria were age 1 to <5 years, weight 5-25 kg, microscopically confirmed uncomplicated P. falciparum malaria, destined to receive AL treatment on outpatient basis, informed consent from parent or guardian and willingness to adherence to study procedures including longer stay on study day 0 for intensive sampling. Parents/guardians of under 5-year-old children with suspected malaria were approached at Mulago Hospital Complex and surrounding public health facilities within 20 km radius.
Exclusion criteria included mixed Plasmodium species infections, signs of severe/complicated malaria, vomiting, diarrhoea, haemoglobin <5 g/dL, age <12 months to avoid repeated draws from very young children, history of AL intake in past 28 days [18] , allergy to AL or milk and intake of medication known to influence CYP450 3A4/5 enzymes. This was necessary to exclude additional influence on LUM exposure from drug-drug interactions such as anticonvulsants (phenobarbitone, carbamazepine), ketoconazole, antituberculosis drugs (rifampicin), antiretrovirals (protease inhibitors, non-nucleotide reverse transcriptase like efavirenz) [2, 19] .
The The study was conducted in conformity with the Helsinki Declaration and ethical conduct of clinical trials. Good Clinical Practice was observed throughout the study. Participation was voluntary, but meals were provided and transport costs were paid.
Study design and randomization. This was an open-label, randomized pharmacokinetic (PK) study to compare the relative bioavailability of LUM among paediatric malaria patients, when AL is administered with milk (arm A) or maize porridge plus vegetable oil (arm B). Permuted block randomization was conducted by an offsite investigator. Sample size calculation was not made, but was empirical. Using nonparametric tests, a minimum of seven participants per group is reported to be adequate, if all of them were to have a common outcome [20] . In intensive PK study designs, 8-12 participants in each group have been reported to provide sufficient data to test for differences in two independent groups, at an adequate power (1-b) of 80%, at a of 5% [21] , also previously demonstrated for LUM bioavailability study [9] . Thus, the target sample size was 48 participants with allocations in ratio of 1:1 for each study arm (24 in A and 24 in B) and plan to enrol 12 individuals per dose block (one and two tablet groups) in each study arm. According to the current standard fixed-weight-based six-dose AL regimen, children with bodyweight of <15 kg received one tablet (20 mgA, 120 mg LUM), whereas children weighing 15-25 kg received two tablets (40 mgA/ 240 mg LUM). For each AL dose group (one or two tablets), six successive blocks of four were prepared, bearing two assignments A and B. At enrolment, participants were stratified into respective dose blocks before randomization.
Food interventions. Participants received each tablet of AL with either 50 mL of milk (A) or 50 mL of maize porridge plus 1.5 mL of vegetable oil (B). Fat content was comparable: 50 mL of ultra-hightemperature-processed (UHT) whole milk (from Sameer Agriculture & Livestock Limited Uganda) contained % 1.7 g of fat, and 50 mL maize porridge plus oil constituted from 2.5 to 3 g of maize flour (4% fat, 0.1-0.125 g fat), and 1.5 mL Mukwano vegetable cooking oil from sunflower seeds (1.5 g of fat) contained in total % 1.6 g of fat.
Study procedures: dosing, sampling and follow-up. Children received standard fixed-weight-based dose of dispersible AL (Coartem â Dispersible 20/120 mg, NAFDAC REG.NO.: A4-1680; Novartis Pharma AG, Basel, Switzerland) as described under study design. Doses were given at 0, 8, 24, 36, 48 and 60 hr. Tablets were dissolved in water (10 mL/tablet) and immediately administered to the participant. The container was rinsed with additional 10 mL, which was given to the participant as well [22] . Both 0-and 8-hr dosing occasions were directly observed, and observation continued for 1 hr after dosing. Participants were allowed to drink water at liberty, but refrained from meals until 3 hr after the first dose when a non-fat-containing meal was served. Supervised third and fifth doses were given after pre-dose samples. The fourth and sixth doses were not supervised, but parents/ guardians were given the assigned food together with dosing instructions.
Prior to fixing intravenous catheter for intense blood sampling, topical anaesthetics (EMLA â patch or cream, lignocaine 25 mg/g and prilocaine 25 mg/g) were applied to relieve pain. Pre-dose, blood (venous, 2-3 mL) was collected for baseline parameters into EDTA tubes for LUM and desbutyllumefantrine (DBL) assays (0.5-1 mL), haematological parameters (0.5-1 mL), malaria microscopy smears (drop, 0.1 mL), parasite genotyping (filter paper spots, 0.4 mL) and into plain tubes for blood chemistry (1 mL).
Intensive PK sampling continued on initial study day (d 0), after first dosing at 1, 1.5, 2, 3, 4, 6, 8 hr, followed by samples pre-dose samples at (24 hr), 2 (48 hr) and after dosing at days (d) 3 (72 hr), d7 (168 hr), d14 (336 hr), d21 (504 hr) and d 28 (672 hr). Malaria microscopy and filter paper spots for PCR were conducted on days 1, 2, 3, 7, 14, 21 and 28. Haematological and blood chemistry parameters were on days 0, 7 and 28.
For the determination of LUM and DBL concentrations, venous blood (0.5-1 mL) was collected in EDTA tubes and immediately centrifuged at 1500 9 g for 5 min. [23] . Separated plasma was put in cryovials and chilled under cover of ice chips for 8-10 hr before final storage at À80°C. In total, each child provided between 11 and 17 mL of blood over the 28-day follow-up period.
Microscopy laboratory methods. Blood smears (BS) were prepared and stained with Giemsa. Parasite density was determined as asexual malaria parasites counted against 200 white blood cells (WBCs) in a thick BS and multiplied by 40 with assumption of 8000 WBC/lL [18] . Slides were confirmed negative after repeated examination of fields containing 1000 WBCs by two microscopists.
Lumefantrine assay. A liquid chromatography tandem mass spectrometry (LCMS/MS) method was used for the simultaneous determination of LUM and DBL concentrations in human plasma (100 lL) [24] . The validated quantification range was 21-529 ng/mL for LUM and 1.9-47 ng/mL for DBL. Dilution of concentrations over the upper limit of quantification was performed whenever needed [24] . Inter-and intra-assay precision was <10% coefficient of variation (CV) for all levels of both LUM and DBL. Accuracy was within À9% to +6% for all levels of both LUM and DBL.
Pharmacokinetic methods. Individual actual sampling time was used for all calculations. Lumefantrine PK parameters were determined by non-compartmental methods based on intense concentration data from venous plasma, after extravascular dose, using WinNonlin (Phoenix WinNonLin Version 6.4, 2005-2014, Pharsight, a CertaraTM company, St. Louis, MO, USA). Time of onset of drug absorption (T lag ), maximum concentration (C max ) and time to reach C max (T max ) were taken directly from observed data. Area under concentrationtime curve from 0 to 8 hr (AUC 0-8 hr ) was estimated with linear up log-down trapezoidal rule. Partial areas from day 7 to 28 were estimated using area under the log concentration-time curve. Elimination rate (K e ) was derived from the negative slope of the fitted line extended with a linear fit using the last three data points between day 7 and 28. The half-life was derived from Ln2/K e . Individuals with nonzero baseline concentrations were considered for baseline correction and inclusion criteria for the evaluation were if the concentration was (i) less than the day 28 median LUM level for this population and (ii) <5% of their C max . Baseline correction was performed by subtraction of the individual pre-dose concentrations.
Malaria parasite genotyping. Parasite genotyping was performed to differentiate recrudescence from re-infection. DNA was extracted from dried blood spots on filter papers using QiaAmp â DNA Micro kit, Qiagen Inc., Valencia, CA, USA. The P. falciparum merozoite surface protein 2 gene (msp2) was genotyped by nested PCR using fluorescently labelled primers amplifying the polymorphic region of the gene. Fragment sizes were determined by capillary electrophoresis on an ABI 3730 DNA sequencer (Applied Biosystems, Foster City, CA, USA). Data were analysed using GeneMapper software (Applied Biosystems) [25] .
Study outcome. The primary PK outcome was early LUM exposure measured as area under concentration-time curve between 0 up to 8 hr after the first dose (AUC 0-8 hr ). Other LUM PK outcome included time of onset of absorption (T lag ), peak concentrations (C max ) and time to C max (T max ) after the first dose. Thereafter, patients completed the standard six doses. Secondary outcome included day 7 concentrations (d7 LUM ), truncated LUM PK exposure between days 7 and study end-point on day 28 (AUC d7-28 ), and day 28 malaria treatment outcome defined according to day 28 PCR-adjusted parasitological response [18] .
Statistical evaluations. Statistical comparisons were made using STATA version 12.1 (1985-2011; StataCorp LP, College Station, Texas, USA). PK parameter estimates were non-normally distributed. Two independent group comparisons of non-normally distributed parameter estimates (T lag , C max , T max , AUC 0-8 hr ) were made using Wilcoxon rank-sum (Mann-Whitney) test (p < 0.05). In addition, two group mean comparisons were made using parametric two-sample ttest (unpaired, unequal variance, Welch test) using log-transformed AUC 0-8 hr parameter estimates, the dependent variables for bioequivalence evaluations (BE). Variabilities in early exposure (logtransformed AUC 0-8 hr ) across food study arms and dose groups were compared using F-test for equality of variance by Brown and Forsythe alternatives [26] . Correlations between covariates and outcome parameters were explored using Kendall correlation (p < 0.05).
Relative bioavailability evaluations. Relative oral bioavailability of LUM was assessed by two-sample t-test for groups with unequal variance comparison of log-transformed AUC 0-8 hr parameter estimates (p < 0.05), with milk (A) as reference and maize porridge plus oil (B) as test arm. However, the traditional average BE could not be adequately employed for the combined dose groups receiving one or two tablets, due to differences in AUC 0-8 hr for one and two tablets groups in A, but not in B. In addition, there was an imbalance in numbers of evaluable individuals per dose group in each arm. Because we had two dose groups per food arm, bioavailability comparisons were re-assessed using dose-adjusted AUC 0-8 hr . For each individual, the dose-corrected AUC 0-8 hr (hr/ mL/kg = 91000 hr/L/kg) was obtained from dividing the individual AUC (hr lg/mL) by the administered corresponding LUM weightadjusted dose (single LUM dose/body-weight = LUM mg/ kg = LUM 9 1000 lg/kg).
Results

Study population.
A total of 41 children were randomized, 21 to study arm A (milk, n = 12 received one tablet, n = 9 for two tablets) and 20 to arm B (maize porridge plus oil n = 12 received one tablet, n = 8 for two tablets). Eight of 41 were not evaluable for the primary PK outcome: three in whom further intensive sampling could not be performed, one due to unfortunate loss of samples at peak hours and four had significant baseline LUM concentrations. Of the remaining 33 children, 16 participated in study arm A including 10 in the one tablet group along with six in the two tablet group. Seventeen participated in study arm B, nine in the one tablet and eight in the two tablet dose group. Baseline characteristics were comparable between the two arms A and B ( [18] , due to withdrawal after poor compliance to study protocol, withdrawn consent, initial misclassification as false positive and loss to follow-up. (table 2) . Lag time was variable across both arms with no obvious difference in absorption patterns. Among 16 of 33 profiles, seven from A and nine from B, it was not possible to accurately determine T max and C max because C max was registered at the last eighth hour, just before administration of the second dose. Therefore, T max was in these cases set at eighth hour. Wide interindividual variability in LUM exposure was noted across both food arms as shown by corresponding high CV values (CV%) for C max and AUC 0-8 hr estimates (table 2) , with one outlier in each group ( fig. 1 ). There was less variability in exposure in arm B compared to A. This was in essence due to much greater variability in the one tablet group in food arm A compared to one tablet group in food arm B (table 2, fig. 3 ). Comparing dose groups across the two arms, comparable AUC 0-8 hr estimates were found among both one and two tablet children in B (p = 0.98). However with A, there was a non-significant trend towards smaller children receiving one tablet exhibiting systematically lower exposures compared with the larger children receiving two tablets per dose. AUC 0-8 hr estimates correlated well with C max (s = 0.73, p = 0.000), but only poorly with AUC day7-28 (s = 0.29, p = 0.038) and d7 LUM (s = 0.27, p = 0.050).
Lumefantrine pharmacokinetics after multiple doses. Twenty-six of the 33 children attending sampling on day 0 completed follow-up to day 28. Reasons for premature withdrawal were failure to comply to study protocol (n = 4), persistent vomiting and aggravated anaemia on day 1, which necessitated treatment with parenteral artesunate (n = 1). Two had initial misclassification as parasite negative.
After multiple doses, d7 LUM and AUC day7-28 were comparable between the two study arms (table 3) . The median d7 LUM in all these <5-year-old falciparum malaria patients was 343 (136-9647) ng/mL. Overall, combining A and B, children who received two tablets (>15 kg, resulted LUM weightadjusted dose of 13.8-16.0 mg/kg/dose) had higher concentrations compared with those who received one tablet (<15 kg, LUM of 8.3-12.6 mg/kg/dose) (table 2), with median d7 LUM Fig. 1 . Individual (symbols) plasma lumefantrine concentrations over time after the first dose of artemether-lumefantrine under different dose groups (1 = 120 mg lumefantrin (LUM), and 2 = 240 mg LUM) in each study arm (A: milk, B: maize porridge plus oil). A1: one tablet, A with an outlier with points at 6 and 8 hr (10,597 and 11,544 ng/mL, respectively). B1: one tablet, B. A2: two tablets, A with an outlier with points at 6 and 8 hr (8367 and 9592 ng/mL, respectively); B2: two tablets, B with an outlier with a point at 8 hr (6684 ng/mL).
(505 versus 289 ng/mL, p = 0.02) and AUC d7-28 (108 versus 41 hr*lg/mL, p = 0.006) (table 3). However, when adjusted for mg/kg dose of LUM, exposures were not significantly higher in the two compared to one tablet group [day 7 (31.6 (11.98-602. 
Tolerability profile.
Overall, AL was well tolerated and treatment was completed by all children, including the one with ETF whose AL treatment was resumed after three intravenous doses of i.v. artesunate given within 24 hr. Vomiting was observed in two children beyond 4 hr after the first dose and diarrhoea was registered among two children on study day 2. No serious adverse events were reported.
Discussion
Our findings indicate that among children <5 years, with uncomplicated malaria, absorption of LUM is comparable when AL is co-administered with either maize porridge fortified with vegetable oil or milk. This is most probably attributed to comparable fat content.
LUM absorption was assessed by early exposure [AUC (0-8 hr) ]. Overall exposure (AUC from zero to infinity) could not be accurately established as this study was carried out in symptomatic non-hospitalized children, which made repeated sampling over long time periods difficult, and all occasions of dose and food intake could not be supervised. Intensive sampling was only possible up to 8 hr when a second treatment dose had to be administered. Relative oral bioavailability for drugs with long half-lives is best assessed after a single dose [27] . With subsequent dosing, superpositioned accumulation of drug occurs. In our earlier single dose, healthy adult volunteer study (n = 11 pairs, milk versus maize porridge plus oil), partial area, AUC (0-8 hr) correlated well with AUC (0-48 hr) [16] , indicating that AUC (0-8 hr) is an acceptable measure of the extent of LUM absorption. Among the adult volunteers in the previous study, the bioequivalence criteria were met. The AUC (0-8 hr) for adult volunteers and the children in the present study patients is not significantly different [median (range) for milk arms: 5.4 (4.2-10.1) versus 6.6 (0.46-36.2) lg/mL, and maize porridge plus oil: 8.4 (3.4-14.5) versus 7.4 (1.6-11.9) lg/mL for adults and children, respectively].
In the preceding explorative healthy volunteer study, both fasted and maize porridge groups demonstrated similarly poor oral bioavailability of LUM [16] . Thus, inclusion of a 'maize porridge only' study arm would have been unethical in this group of children suffering from potentially life-threatening falciparum malaria. Premji and colleagues have advocated for adequacy of African dietary fat content for LUM absorption based on evaluation of their dietary composition [28] . However, without clinical and bioavailability studies, the relevance of the recommendation remains unsubstantiated. Malaria patients are often averse to food. The limited food intake during sickness may not provide enough fat to adequately enhance LUM absorption, until patients resume normal appetite [4] . In a hospital setting, allocated milk portions of 200 mL were completed on only 43% occasions [29] . Our food rationing strategy aimed at prescribing minimal but sufficient volumes (50-100 mL) of food ensuring adequacy of fat content (>1.2 g of fat) based on recommendations from Ashley and colleagues [9] and findings from our study in adults [16] .
In this real-life paediatric clinical study, traditional average BE could not be adequately employed because of lack of proportionality in numbers of evaluable individuals per dose block in each arm, after exclusion of participants with detectable baseline LUM. However, the intention was not to meet the stringent BE criteria used for the assessment of comparative bioavailability of generic products. Another reason was the high variability in data that did not allow the use of standard ABE criteria (acceptance bioequivalent interval for ratios of group means between 80% and 125%). Thus, the confident interval approach had to be used for the relative bioavailability comparisons.
Despite the observed difference in variance of AUC (0-8 hr) estimates across the two arms, it can be claimed that overall maize porridge fortified with oil increased LUM absorption to the same magnitude as with milk when assessed by early exposure [AUC (0-8 hr) ]. In addition, the interindividual variability was significantly lower with maize porridge plus oil regardless of the number of tablets, which explicitly suggests an advantage from an efficacy point of view with a possibly reduced risk for subtherapeutic LUM concentrations. A further advantage is that smaller and larger children achieved approximately similar AUC (0-8 hr) in the maize + oil group. However, in the milk group, smaller children had much lower LUM exposures compared with bigger children (table 2, fig. 3 ). It is quite possible that this difference in exposure for one and two tablets in the milk group was caused by a high general variability and not a true difference that would be consistent in a larger patient group.
In this study, with a limited dose range of 8.3-16.0 mg/kg/ dose, there was no overall clear relationship between dose administered and exposure possibly due to marked interindividual variations in PK processes. The number of participants was sufficient to assess our PK objective, but insufficient for determining which patient variables could significantly explain the variability. Interpatient variability in LUM PK exposure may be partially attributed to differences in metabolism due to maturation (age) [4, 30] ; polymorphism of CYP3A4 enzymes [31] ; metabolism or p-glycoprotein efflux activity in intestinal epithelial cells [32] ; physiological differences that may include food effect on gastric emptying and gastrointestinal (GIT) Other important factors such as pH of GIT contents may affect drug stability and solubility and hepatic blood flow [33] . After multiple doses, day 7 plasma LUM concentration is a surrogate marker for overall LUM exposure [34] . Correlation of plasma d7 LUM with therapeutic response is commonly discussed in relation to cut-off references of 280 ng/mL suggested among adult Thai patients in an area of highly drugresistant P. falciparum [4] and 175 ng/mL among Thai patients in low malaria transmission area [35] . In our study, smaller children (<15 kg, dosed one tablet) had significantly lower LUM exposure than bigger children (>15 kg, dosed two tablets) (table 3). All children who received two tablets of AL exceeded 280 ng/mL, except for one child whose d7 LUM was 192 ng/mL. However among children who received one tablet of AL, of 16 three had d7 LUM <175 ng/mL and seven had levels <280 ng/mL.
In a recently published large pooled data study, PCRadjusted P. falciparum treatment failure was significantly higher in Asian children weighing 10-15 kg receiving a total LUM dose of less than 60 mg/kg. In Africa, the risk of treatment failure was highest in malnourished children aged 1--3 years [7] . This is consistent with the suggestion that current dose regimen may not be optimal for children weighing <15 kg who receive one tablet based on the current fixedweight dose categories [7] .
The d7 LUM concentration ranges from our study population are comparable to earlier results during AL treatment for acute uncomplicated falciparum malaria among <5-year-old Ugandans (mean d7 LUM : 376 versus 249 ng/mL among supervised and unsupervised treatments, respectively) [36, 37] and among Ugandan children aged 5-13 years (median d7 LUM : 323.3 ng/ mL) [38] . However, lower d7 LUM (median: 205 ng/mL) was reported in Tanzania, among children aged ≤5 years old with Fig. 3 . Distribution of AUC 0-8 hr (hr*ng/mL) estimates, after the first artemether-lumefantrine dose across food arms (A and B) and dose groups (1 and 2). Food: A: milk, B: maize porridge plus oil. Dose groups: 1 = one tablet containing 120 mg lumefantrine (LUM); 2 = two tablets, total 240 mg LUM. Table 3 . Lumefantrine pharmacokinetic parameters after standard six oral doses of artemether-lumefantrine among <5-year-old children with uncomplicated falciparum malaria. acute uncomplicated falciparum malaria who received unsupervised AL treatment at home [39] . Our findings are consistent with earlier reports of high interindividual variability in LUM exposure between patients [4] [5] [6] 16, [36] [37] [38] [39] [40] . The variation in d7 LUM concentrations in published studies is diverse ranging from 8-to 15-fold difference within similar dose and age category [36] [37] [38] to >130-fold difference regardless of age and dose categories [6, 36] . Reduction in group variance for oral LUM bioavailability was observed when AL was taken with food, particularly fat-containing food as opposed to liquids [16, 40] . In the present study, less interindividual variations in LUM exposure were noted in oil-fortified maize porridge group compared to those in the milk group, especially among smaller children (table 3, fig. 3 ). This may be attributed to the fact that porridge as a semi-solid enriched with fat could be associated with a slower gastric emptying giving time for more extensive absorption [40, 41] .
Compared with earlier controlled clinical trials, recent reallife studies have reported trends towards lower d7 LUM and associated with increasing risk of treatment failure among children receiving AL for the treatment of uncomplicated falciparum malaria [39, 42] . This further supports the need for practical food alternatives to improve LUM absorption. The World Health Organization emphasizes that as long as the malaria parasites are still susceptible to existing medicines, dose optimization and proper utilization are crucial to provide sufficient drug pressure in order to delay selection of drugs for resistance development as well as to reduce transmission [43, 44] .
Conclusion
In this patient study, comparable oral bioavailability of LUM was observed when AL was supplemented with either milk or maize porridge fortified with cooking vegetable oil. Our findings suggest that when milk is not available, oil-fortified maize porridge can be used to optimize the absorption of LUM in children with uncomplicated falciparum malaria. Importantly, the interindividual differences in LUM AUC (0-8 hr) was found to be significantly lower when administered with oil-fortified maize porridge as compared to administration with milk. The low LUM exposure in children <15 kg receiving only one AL tablet needs further attention and indicates a need for revised dosage recommendations.
